Fullspan Health Introduces Healthline AI Agent

Amid the fast-growing use of artificial intelligence search tools for health-related queries, a new AI agent from Fullspan Health is seeking to counter the inaccuracies and hallucinations of other chatbots by providing users with answers drawn only from medically reviewed information. 

The Healthline AI conversational agent has been trained exclusively on validated information from Fullspan parent company RVO Health’s properties, which include Healthline and Healthgrades, among others. Patients can use the tool to ask questions about specific conditions, access support resources, locate nearby healthcare providers and book appointments. 

The publisher unveiled the AI this week with an initial focus on Type 2 diabetes, with plans to eventually expand into other conditions. 

For its healthcare and pharma partners, Fullspan is pitching the chatbot as a vehicle to reach highly engaged users actively seeking health information, in a brand-safe way thanks to Healthline AI’s validated content and clinical guardrails. The company said the tech will ultimately scale across its audience of 63 million monthly users. 

The new AI offering arrives not long after Fullspan pulled back the curtain on an updated platform aimed at serving patients throughout the entire care journey. The new model combines the RVO Health content portfolio with a suite of tools spanning patient navigation, telehealth, pharmacy access and adherence support, all designed to unify a wide range of patient support resources in one place. 

 solli’s Final Thoughts 

As AI use skyrockets across the healthcare ecosystem, trust in the technology remains a pressing issue. Patients and healthcare professionals alike are (rightfully) wary of the automated answers they receive and express concern about whether sponsorships of individual tools may wield undue influence over their outputs. 

New arrivals like Healthline AI and the clinician-focused, HIPAA-compliant AI search tool that Healio began rolling out last fall may offer a blueprint for other publishers and tech developers—and health and pharma advertisers—looking to assuage those fears. A recent report found that, in a survey of about 350 U.S. clinicians, more than half said a top factor in evaluating new AI tools is whether they’ve been built by a trusted medical resource—not a general tech company.  

Indeed, Fullspan’s own research found that close to 70% of consumers said they’d find a conversational AI agent from Healthline more trustworthy than ChatGPT, further illustrating a resounding openness across the healthcare spectrum to AI tools from tried-and-true sources.